Soluble urokinase plasminogen activator receptor (suPAR) independently predicts chronic kidney disease (CKD) incidence and progression. Apolipoprotein L1 (APOL1) gene variants G1 and G2, but not the reference allele (G0), are associated with an increased risk of CKD in individuals of recent African ancestry. Here we show in two large, unrelated cohorts that decline in kidney function associated with APOL1 risk variants was dependent on plasma suPAR levels: APOL1-related risk was attenuated in patients with lower suPAR, and strengthened in those with higher suPAR levels. Mechanistically, surface plasmon resonance studies identified high-affinity interactions between suPAR, APOL1 and a v b 3 integrin, whereby APOL1 protein variants G1 and G2 exhibited higher affinity for suPAR-activated avb3 integrin than APOL1 G0. APOL1 G1 or G2 augments a v b 3 integrin activation and causes proteinuria in mice in a suPAR-dependent manner. The synergy of circulating factor suPAR and APOL1 G1 or G2 on a v b 3 integrin activation is a mechanism for CKD.
In individuals of recent African ancestry, variants in APOL1 have been associated with certain forms of CKD. Carriers of two risk alleles (either two of G1 or G2; G1/G1 or G2/G2, or one each of G1 and G2; G1/G2) are at heightened risk for focal segmental glomerulosclerosis (FSGS), HIV-associated nephropathy and hypertension-attributed kidney disease [1] [2] [3] [4] [5] . The molecular mechanisms underlying the association between APOL1 risk variants and CKD remain unclear. Inflammation is thought to be a major contributor to APOL1-related CKD, because APOL1 expression in podocytes is induced by components of innate immune pathways, such as those of interferons and Toll-like receptors 6 . Moreover, the APOL1 high-risk genotype is strongly associated with nephropathy in people with HIV, a state of immune dysregulation 7, 8 . However, a puzzling observation is that not all individuals carrying the high-risk APOL1 genotype develop renal disease, and equally, not all transgenic animal models, including models of mice 9 and zebrafish 10 , expressing high-risk APOL1 variants display the expected kidney phenotypes. Taken together, these findings suggest the possibility of a 'second hit' in the pathogenesis of APOL1-associated nephropathy 10 .
SuPAR is a member of the Ly-6/neurotoxin family of signaling proteins and a marker of immune activation that associates with states of systemic inflammation, such as HIV [11] [12] [13] . SuPAR has recently been shown to be strongly predictive of incident CKD 14 , and it is thought to be involved in the pathogenesis of kidney disease, specifically FSGS which is characterized by progressive scarring of the kidney that often leads to renal failure, through the activation of the α v β 3 -integrin signaling pathway on podocytes [15] [16] [17] . Given the strong association of both suPAR and APOL1 genetic risk variants with inflammation and CKD, we sought to determine (i) whether the relationship in African Americans between the APOL1 genotype and decline in kidney function is influenced a r t i c l e s 9 4 6 VOLUME 23 | NUMBER 8 | AUGUST 2017 nature medicine by suPAR levels, and (ii) to identify potential molecular mechanisms that would underlie the interaction between suPAR and APOL1 in the context of CKD.
RESULTS

Clinical characteristics, suPAR levels and APOL1 risk variants
We characterized APOL1 genetic variants and plasma suPAR levels in two separate cohorts of African American individuals: the Emory Cardiovascular Biobank (EmCAB) and the African American Study of Kidney Disease and Hypertension (AASK). The EmCAB cohort consisted of 487 patients with a mean age of 58 ± 12 years, of which 50% were male, 49% had diabetes and 27% had an estimated glomerular filtration rate (eGFR) of <60 ml/min/1.73 m 2 . A total of 73 (15%) cohort members had a high-risk APOL1 genotype (renal risk alleles on both parental chromosomes), whereas 220 (45%) and 194 (40%) had 1 and 0 copies, respectively, of a high-risk haplotype. Individuals in the APOL1 high-risk-genotype group had lower eGFRs and higher suPAR levels at baseline ( Table 1) . However, when adjusted for suPAR levels, APOL1 genotype was not independently associated with baseline kidney function (Supplementary Table 1 ). Plasma suPAR levels were approximately 20% higher in the APOL1 high-risk group than in the low-risk group (P = 0.001). In a multivariable analysis adjusted for age, gender, body-mass index, smoking history, hypertension, diabetes mellitus and baseline eGFR, those with APOL1 high-risk status remained independently associated with higher suPAR levels (Supplementary Table 1 ).
The AASK cohort consisted of 607 people with a mean age of 54 ± 11 years; 60% were male, and the mean baseline eGFR was 48 ml/min/1.73 m 2 . Individuals with two risk alleles of APOL1 genotypes (n = 143, 23.6%) were younger, had a lower prevalence of heart disease and a lower eGFR at baseline ( Table 1) . The difference in plasma suPAR levels between patients with one or zero and those with two risk alleles of APOL1 (4,700 pg/ml and 4,338 pg/ml, respectively) was not statistically significant (P = 0.07). There was no difference between suPAR levels among the 199 and 265 participants with no or one risk allele(s) of APOL1, respectively (4,354 pg/ml and 4,322 pg/ml; P = 0.78).
The decline in kidney function attributed to APOL1 risk variants is dependent on suPAR We next examined the association between suPAR, APOL1 risk variants and eGFR decline in both cohorts. In the EmCAB cohort, the mean decline in eGFR per year was −4.00 (95% CI 3.3, 4.6) and −3.4 (95% CI 2.9, 3.8) ml/min/1.73 m 2 , respectively, in the APOL1 high-risk group and low-risk group. In an analysis adjusted for age, gender, body-mass index, smoking history, hypertension and diabetes, the APOL1 risk genotype was associated with faster eGFR decline in the presence of suPAR >3,000 pg/ml, but not when levels were <3,000 pg/ml (P for interaction = 0.03) ( Table 2 ). In the AASK cohort, the mean eGFR decline per year was −2.2 ml/min/1.73 m 2 per year for the APOL1 two-risk-allele group, as compared to −1.5 ml/min/1.73 m 2 per year for those with one or zero risk alleles. In our adjusted analysis, the APOL1 high-risk genotype was associated with faster eGFR decline in the presence of suPAR levels >3,000 pg/ml but not <3,000 pg/ml (P for interaction = 0.006), similar to the EmCAB cohort. In AASK, continuous analysis suggested that the threshold for decline in kidney function associated with suPAR was lower among people with two risk alleles of APOL1 (Fig. 1) .
In summary, suPAR levels were a substantial modifier of the association between APOL1 genotype and subsequent eGFR decline. Higher baseline suPAR levels were associated with a significantly greater yearly decline in kidney function in patients with two APOL1 risk alleles than those in patients with one or zero alleles ( Fig. 1) , which suggests that suPAR-related decline might be dependent on the presence of the APOL1 risk allele.
APOL1 proteins bind suPAR and active a v b 3 integrin with high affinity Given the strong association noted in African American individuals between suPAR levels, APOL1 risk alleles and decline in kidney function, as well as the previous evidence for a role of suPAR in kidney disease through the activation of α v β 3 integrin 12,13 , we next explored the possibility of a protein-protein interaction between suPAR, APOL1 and α v β 3 integrin. To this end, we performed a series of surface plasmon resonance (SPR) assays using recombinant APOL1 proteins (Supplementary Fig. 1 ). Given that circulating APOL1 is a component of a lipid-rich trypanolytic complex that has an electrophoretic mobility of high-density lipoprotein (HDL) particles 18 , we assessed the functionality of recombinant APOL1 proteins by measuring the binding affinity of APOL1 to HDL. All three variant APOL1 proteins (G0, G1 and G2) exhibited similarly high affinities for HDL (K D , ~150 nM; Supplementary Fig. 2 ). Next, we investigated whether APOL1 can directly bind suPAR. Of note, all three variant APOL1 proteins exhibited very high affinities for suPAR (K D , ~10-20 nM; Fig. 2a ). These data also suggest that suPAR-APOL1 interactions are likely not mediated by the C-terminal domain of APOL1, given that amino acids that are altered in both APOL1 risk variants are situated in the C-terminal domain. We next tested whether the variant APOL1 proteins can also bind α v β 3 and/or α 3 β 1 , two major integrins in podocytes. Consistently with a previous report 17 , suPAR exhibited a high affinity for α v β 3 integrin (K D = ~3 nM; Fig. 2b ). The affinity of suPAR for α v β 3 was not considerably altered in the presence of Mn 2+ , a potent, nonspecific activator of integrins 19 ( Fig. 2b ; in the presence of Mn 2+ , integrin is defined to be in the active form). In contrast to suPAR, all three variant APOL1 proteins exhibited moderate to low affinities for inactive α v β 3 integrin (K D = 574 nM (G0); K D = 528 nM (G1); K D = 10,730 nM (G2); Fig. 2c ), and very low affinity for α 3 β 1 integrin (K D >1 mM; Fig. 2d) . Unexpectedly, the affinity of all three variant APOL1 proteins for α v β 3 but not α 3 β 1 integrin was at least 100-fold higher in the presence of Mn 2+ (K D = ~7 nM; Fig. 2c,e) . The effect was most pronounced for the G2 APOL1 variant, which bound the active form of α v β 3 integrin with a more than 1,000-fold greater affinity than that of the nonactive form. Taken together, these data suggest that APOL1 might exert a synergistic interaction with suPAR in potentiating the activation of α v β 3 integrin. To examine the formation of such a potential triple complex, we performed a SPR assay in which the concentration of suPAR was increased in the presence of constant concentrations of α v β 3 and APOL1. Although all three variant APOL1 proteins exhibited similarly low affinities for suPAR in the presence of α v β 3 ( Fig. 2f and Supplementary Fig. 2b ), the APOL1 risk variants G1 and G2 exhibited a dramatically higher affinity (K D = 277 nM, K D = 24 nM, respectively) for suPAR in the presence of α v β 3 with Mn 2+ , comparing with APOL1 G0 (K D = 665 nM) ( Fig. 2f and Supplementary Fig. 2b ).
We detected increased binding affinities for both the APOL1 G1 and G2 risk variants, and, to a greater extent, for the APOL1 G2 riskvariant protein (Supplementary Fig. 2b ). Together, these data using SPR identify high-affinity interactions between recombinant APOL1 and suPAR, and a synergistic effect between APOL1 and suPAR in the activation of αvβ3 integrin, as well as a difference between the nonrisk and risk-variant APOL1 proteins in such activation. The model includes all listed covariates, including the interaction terms. Linear mixed-effects model was used with both data sets to account for within-subject correlations among repeated measures of eGFR over time (random subject-specific intercept and random time effect). Age and BMI were centered at the study-specific mean, respectively. Diabetes status was not included in the AASK model, given that no cohort members had diabetes. Hypertension in the AASK cohort refers to blood pressure randomization group. The relevant interaction term, including suPAR, APOL1 and follow-up time, is highlighted in bold. P values less than 0.05 were considered to be statistically significant. Linear mixed-effects model was used. Asterisks denote an interaction term. suPAR (pg/ml) 7,000 9,000 1,000 3,000 5,000
suPAR (pg/ml) 7,000 9,000 Figure 1 Synergy of an APOL1 high-risk genotype and suPAR levels determines yearly loss of kidney function. (a,b) Estimated yearly change in estimated glomerular filtration rate (eGFR) according to APOL1 status (green, low risk; red, high risk) and continuous levels of suPAR at cohort enrollment for the Emory Cardiovascular Biobank (EmCAB; n = 487) (a) and the African American Study of Kidney Disease and Hypertension cohort (AASK; n = 607) (b). Yearly change in eGFR was estimated from linear mixed-effects models of eGFR adjusted for age, sex, body-mass index, hypertension, diabetes mellitus (in EmCAB), smoking status, randomization group (in AASK) and suPAR level in both baseline levels and slope over time. In EmCAB, suPAR was log-transformed. In AASK, suPAR was log-transformed and modeled using restricted cubic splines to allow for deviations from log linearity. SuPAR and APOL1 risk variants synergize to activate a v b 3 integrin on podocytes Experiments using recombinant proteins suggested the formation of a triple complex between suPAR, α v β 3 integrin and APOL1. To examine whether such a complex could be formed on the cell membrane, we expressed the reference allele APOL1 (i.e., G0), suPAR and β 3 integrin in human embryonic kidney (HEK) 293T cells, and used cell lysates for immunoprecipitation experiments. Both suPAR and β 3 integrin co-immunoprecipitated with APOL1 G0 (Fig. 3a) , and APOL1 G0 co-immunoprecipitated with both suPAR and, to a lesser degree, β 3 integrin (Fig. 3b) . Taken together with previous studies 15 , showing that suPAR interacts with β 3 integrin, these data suggest that the tripartite-protein complex might form on the cell membrane. We next tested whether APOL1 G0 synergizes with suPAR in the activation of β 3 integrin on human cultured podocytes by using sera from individuals with FSGS as an exogenous source. We modified the original assay 17 to measure the ratio of activated β 3 integrin level (as determined by staining for AP5 , a monoclonal antibody that specifically recognizes the active conformation of β 3 integrin) over the total amount of focal adhesion, as determined by staining with an anti-paxillin antibody (Supplementary Fig. 3a-c) . We added Mn 2+ to determine the maximal level of β 3 -integrin activation in the assay ( Supplementary Fig. 3b,c) . In all subsequent experiments, we compared the level of activation to that of serum from a healthy individual, normalized to 1. Although suPAR levels similar to those of healthy individuals (2,000 pg/ml) did not induce significant β 3 integrin activation, high suPAR levels (10,000 pg/ml) did (Fig. 3c) , as previously reported 17 . Importantly, the presence of APOL1 proteins at concentrations similar to those in plasma (15 µg/ml) 20 did not result in significant β 3 -integrin activation (Fig. 3c) . By contrast, the addition of both suPAR and APOL1 G1 and G2 proteins, but not of the reference protein APOL1 G0, resulted in potent activation of β 3 integrin (Fig. 3c,d) . In addition to β 3 -integrin activation, a combination of both suPAR and APOL1 G1 and G2 proteins also resulted in substantial cell detachment (Supplementary Fig. 4a) , which suggests that a combination of these two proteins results in toxic effects with regard to podocytes in culture. The ability of suPAR, as well as a combination of suPAR and APOL1 risk-variant proteins, to induce β 3 -integrin activation is consistent with the integrin activation observed in the presence of sera from individuals with FSGS carrying or not carrying APOL1 risk alleles (Fig. 3e) . Indeed, two of the serum samples from individuals who have FSGS and carry two risk alleles resulted in such dramatic cell detachment (striped column, Fig. 3e ) that it impaired our ability to accurately quantify β 3 -integrin activation.
More detailed concentration analysis showed that APOL1 G1 and G2 required higher levels of suPAR (≥3,500 pg/ml; Fig. 3f ) to induce integrin activation. For a given suPAR concentration (5,000 pg/ml), APOL1 G2 induced potent integrin activation at lower concentrations (0.5 µg/ml) than were required for induction by APOL1 G1 protein (15 µg/ml) (Fig. 3g) , consistent with its higher binding affinity, as determined by SPR. Of note, physiological concentrations of APOL1 proteins in circulation range from 0.4 to 16 µg/ml (median, 4 µg/ml) 20 . Taken together, these data provide further support for the hypothesis that high suPAR levels synergize with APOL1 G1 and G2 proteins to induce not only potent β 3 -integrin activation, but also podocyte detachment.
Given that integrin activation is linked to the regulation of autophagy in many cells, and because APOL1 risk alleles have been linked to the induction of nonfunctional autophagosomes 21, 22 , we next examined the effects of suPAR and APOL1 proteins on the formation of autophagosomes. To this end, we determined the percentage of cells that stained positive for the presence of autophagosomes, using anti-LC3B antibody as an endogenous autophagic marker 23 . Potent integrin activation by Mn 2+ or high suPAR concentrations that also induced integrin activation (Fig. 3c) resulted in a significant increase in the number of cells with autophagosomes (Supplementary Fig. 4b ; P ≤ 0.003). Indeed, suPAR-induced autophagosome formation was blocked by the anti-suPAR antibody (Supplementary Fig. 4c ). We used rapamycin, an mTOR inhibitor, as a positive control. In addition, APOL1 G1 and G2 proteins, but not the G0 protein, also increased the number of cells with autophagosomes in the absence of exogenous suPAR (Supplementary Fig. 4d ). The presence of both APOL1 G1 or G2 and suPAR at a concentration that results in integrin activation (Fig. 3c) led to significant cell detachment (Supplementary Fig. 4a ; P < 0.001), thus impairing the quantification of cells with autophagosomes (striped black graphs in Supplementary Fig. 4b ). Taken together, these data suggest that autophagosome formation in podocytes can be induced by suPAR-dependent α v β 3 -integrin activation, as well as by APOL1 G1 and G2 mutant proteins.
Expression of APOL1 G1 and G2 but not the G0 allele induces kidney injury in mice
The foregoing association data in human cohorts, taken together with experiments using recombinant proteins and podocytes in culture, suggest that expression of the APOL1 G1 and G2 risk alleles 
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Figure 4
In vivo gene delivery of APOL1 G1 and G2, but not of G0, gene constructs caused proteinuria and podocyte foot-process effacement in wild-type mice, but not in Plaur −/− mice. To express APOL1 in C57BL/6 mice or Plaur −/− mice, in vivo gene delivery was performed and the kidney phenotype evaluated 16 h after APOL1 gene (G0, G1 and G2) injection. (a) APOL1 protein could be detected in both the glomerulus and liver of injected animals. Double immunostaining of APOL1 (green) and synaptopodin (synpo, red), a podocyte marker. VC, pcDNA 3.1 vector control. Scale bars, 10 µm. (b) Transmission electron microscopy (TEM) analysis of the kidney glomeruli in APOL1 gene (G0, G1 and G2) engineered mice. TEM images display podocyte foot processes. Scale bars, 1 µm. (c,d) Examination of proteinuria (c) and serum APOL1 levels (d) in animals into which APOL1 genes were injected (n = 7 for VC; n = 5 for APOL1 G0; n = 3 for APOL1 G1; n = 7 for APOL1 G2; n = 3 for all Plaur −/− mice). Analysis of urinary protein is shown as albumin (mg)/creatinine (g) ratio before (T0) and 16 h after (T16) gene delivery. Data are shown as means ± s.e.m. One-way ANOVA, followed by Tukey′s multiple-comparison test in which values at T16 were compared to those at T0; *P < 0.05, **P < 0.01. Welch's ANOVA was used when unequal variances were noted between groups (P = 0.014). (e) APOL1 G2 protein was detected in the glomerulus and liver of Plaur −/− mice 16 h after the gene was injected into a tail vein. Double immunostaining of Plaur −/− (green) and synaptopodin (synpo, red). VC, pcDNA 3.1 vector control. Scale bars, 10 µm.
might result in suPAR-dependent podocyte injury. To this end, we injected DNA encoding each of three variant APOL1 proteins into the tail vein of wild-type (WT) mice, as previously described 24, 25 . 16 h after APOL1 gene delivery, we were able to detect APOL1 proteins, using immunofluorescence, in both the liver and glomerulus (Fig. 4a) , as well as in the circulation (Fig. 4b) . Of note, mice do not have an APOL1-equivalent gene. Animals expressing human APOL1 G1 and G2, but not G0, protein exhibited significant levels of proteinuria (Fig. 4c) .
There was also foot-process effacement-as determined by electron microscopy of the glomerulus (Fig. 4d) -and induction of β 3 -integrin activation as evidenced by increased staining with AP5 in the glomerulus (Supplementary Fig. 5a ). In addition, the ability of APOL1 proteins to induce proteinuria required the presence of Plaur, the gene encoding both uPAR and suPAR. The expression of APOL1 G2 protein using a gene-delivery technique 24, 25 in uPAR-deficient animals (Plaur −/− ) did not cause significant levels of proteinuria (Fig. 4c) , despite the presence of APOL1 protein in the circulation, glomerulus and liver (Fig. 4d,e) . This finding further supports a role for suPAR (or uPAR) in APOL1-driven kidney injury.
DISCUSSION
This study provides a mechanism for APOL1-associated kidney disease in African Americans. We uncover an interaction between suPAR and APOL1 as they relate to kidney-function decline, and we describe a potential mechanism that underlies this association. We have measured suPAR levels and determined the APOL1 genotypes in two differing cohorts of African American individuals, and found that patients with the high-risk APOL1 variant genotypes exhibited a steeper decline in renal function, than individuals carrying low-risk variants, particularly in the setting of high suPAR levels; this remained true even after adjusting for the relevant covariates. Biochemically, we identify high-affinity interactions between APOL1 and suPAR, as well as between APOL1 and α v β 3 integrin. In addition, we show that the G1 and G2 risk variants of APOL1, but not the reference protein G0, synergize with suPAR in the activation of α v β 3 integrin on podocytes. Finally, the expression of APOL1 G1 and G2 but not G0 proteins in mice resulted in uPAR-dependent proteinuria and foot-process effacement. Taken together, our findings identify a biological link between suPAR and APOL1 interaction in the mediation of kidney disease (Supplementary Fig. 6 ).
The observation that African American individuals with a high-risk APOL1 genotype experience a more rapid decline in eGFR is consistent with what has previously been reported in various cohorts [1] [2] [3] [4] [5] . We found the association to be highly dependent on baseline suPAR levels, and to involve a rapid increase in the magnitude of estimated yearly eGFR decline as suPAR levels increase beyond 3,000 pg/ml. At low suPAR levels (<3,000 pg/ml), there were no notable differences in eGFR decline between the APOL1 high-risk genotypes and the remainder of the cohort. Together, these findings suggest that the presence of elevated suPAR levels is likely to be a major contributor underlying the association between APOL1 genotype and kidney disease. The replication of the APOL1-suPAR interaction in the AASK cohort strengthens our confidence in our findings, given that EmCAB and AASK are cohorts with distinct selection criteria and study design. The EmCAB is an ongoing prospective observational study of patients undergoing cardiac catheterization for various indications, and represents a heterogeneous, high-risk population with less than one-third of the cohort having an eGFR of <60 ml/min/1.73 m 2 . The AASK cohort is an extension of a randomized, controlled trial of individuals with CKD attributed to hypertension, for which enrollment occurred in the late 1990s. Follow-up eGFR was measured for clinical indications in EmCAB-cohort participants, and at semi-annual protocol visits for the AASK cohort. In addition, suPAR levels were measured in the two cohorts using two different kits (Quantikine in EmCAB, and Virogates in AASK) by off-site technicians blinded to the clinical data.
The protein-protein interaction studies identified high-affinity interactions between all three APOL1 protein variants and suPAR. APOL1 exhibited almost ten-fold higher affinity for suPAR than for high-density lipoprotein (HDL). In addition, we show that APOL1 G1, and especially G2, also bind α v β 3 integrin with high affinity, but only if α v β 3 integrin is in the active conformation (i.e., Mn 2+ is present). In keeping with studies using recombinant proteins, higher levels of suPAR were needed to synergize with APOL1 G1 and G2 proteins to induce substantial α v β 3 -integrin activation within cultured human podocytes. Given that concentrations of suPAR in the circulation are fairly low (2,000-10,000 pg/ml) and that APOL1 proteins circulate with HDL, it seems reasonable to assume that the protein complex between suPAR and APOL1, as well as APOL1 and α v β 3 integrin, is confined to the podocyte membrane (Supplementary Fig. 6 ). Although APOL1 risk-variant proteins were linked to the induction of nonfunctional autophagosomes 21, 22 , transgenic animal models expressing high-risk APOL1 variants did not develop the expected kidney phenotypes 9, 10 . Indeed, whereas the addition of both suPAR and APOL1 G1 and G2 proteins resulted in an increase in the number of cells that contained measurable levels of autophagosomes, the most dramatic effect observed when both proteins were present was substantial cell detachment. In addition, whereas APOL1 G1 and G2 proteins could induce the formation of autophagosomes even in the absence of a high concentration of suPAR and resultant β 3 -integrin activation, the presence of suPAR either in circulation or on the podocyte membrane was required for cell detachment. Accordingly, mice lacking the Plaur gene have normal kidneys and do not develop proteinuria after expression of APOL1 G2, which suggests that uPAR is needed to allow for the development of clinically significant APOL1-induced autophagosme dysfunction.
The current experiments do not identify the origin, whether hepatic 26 or from local secretion by podocytes, of the APOL1 proteins involved in suPAR-α v β 3 integrin interactions (Supplementary Fig. 7) . Regardless of the origin of APOL1, our study identifies a molecular mechanism whereby APOL1 risk-variant proteins lead to podocyte injury by synergizing with high levels of suPAR to induce potent α v β 3 -integrin activation on the podocyte membrane. The formation of such a triple complex results in the activation of multiple α v β 3 -integrin signaling pathways, which leads to the formation of autophagosomes, dysregulation of the actin cytoskeleton and, ultimately, cell detachment. Therefore, our results do not challenge a concurrent mechanism for cell injury emanating from podocyte-generated APOL1 proteins, as was previously suggested [27] [28] [29] [30] . Rather, they suggest that, for the podocyte injury to occur, the secreted APOL1 risk-variant protein needs to be internalized by the cell in a urokinase receptor and β 3 -integrin-dependent manner (Supplementary Fig. 6 ) [31] [32] [33] [34] . This rationale is supported by the fact that the APOL1 gene encodes a signal peptide sequence that targets newly synthesized protein for secretion, by the fact that exogenously added APOL1 risk-variant proteins, but not the non-risk-variant, affected endocytic machinery within podocytes (formation of autophagosomes)-the mechanism through which APOL1 risk proteins lyse trypanosomes 29 -and lastly, by studies describing suPAR-β 3 integrin-dependent endocytosis of hantaviruses 35, 36 . Interestingly, a previous study showed that podocyte-specific expression of APOL1 risk variants in mice resulted in moderate podocyte depletion later in life and occasional preeclampsia 9 . It is worth noting that endothelial cells, similarly to podocytes, also express α v β 3 integrin, and therefore, the formation of the triple complex between APOL1, suPAR and α v β 3 integrin might also occur on endothelial cells. In a recent study, podocyte-specific expression of APOL1 risk variants in mice induced albuminuria and effacement of foot processes 37 , in contrast to the findings of another study 9 . Podocyte injury was attributed to altered endosomal trafficking and blocked autophagic flux, ultimately resulting in podocyte loss and glomerular scarring. Given that APOL1 risk-variant proteins did not alter exocytosis of the newly synthesized proteins, it is reasonable on the basis of our study to suggest that observed impairment in the autophagic flux required endocytosis of podocyte-secreted APOL1 proteins through urokinase-receptor-dependent α v β 3 -integrin activation (Supplementary Fig. 6 )-a hypothesis that deserves direct testing.
In summary, our study describes clinical and molecular interactions between suPAR and APOL1, both novel and strong predictors of kidney disease. Because the nephropathologic effect of APOL1 is based on suPAR-mediated α v β 3 -integrin activation, modification of suPAR could be a safe and therapeutic approach to treat CKD in individuals of recent African ancestry.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
